PriceTargets.com logo

GeoVax Labs - GOVX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $7.50
  • Forecasted Upside: 1,855.16%
  • Number of Analysts: 4
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$0.38 As of 12/4/2025 05:00 PM ET
▼ -0.0171 (-4.27%)

This chart shows the closing price for GOVX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New GeoVax Labs Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GOVX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GOVX

Analyst Price Target is $7.50
▲ +1,855.16% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for GeoVax Labs in the last 3 months. The average price target is $7.50, with a high forecast of $8.50 and a low forecast of $6.00. The average price target represents a 1,855.16% upside from the last price of $0.38.

This chart shows the closing price for GOVX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 4 investment analysts is to moderate buy stock in GeoVax Labs. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 2 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 2 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 2 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 2 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/19/2025D. Boral CapitalLower TargetBuy ➝ Buy$9.00 ➝ $6.00
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/26/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$9.00
8/7/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$9.00
7/29/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$9.00
7/17/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$9.00
6/16/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$9.00
5/2/2025D. Boral CapitalLower TargetBuy ➝ Buy$14.00 ➝ $9.00
4/16/2025HC WainwrightReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
4/15/2025Alliance Global PartnersLower TargetBuy ➝ Buy$15.00 ➝ $8.50
4/10/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
3/28/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
2/27/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
1/31/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
1/16/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
12/18/2024D. Boral CapitalReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
11/19/2024D. Boral CapitalReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
11/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
11/11/2024Alliance Global PartnersInitiated CoverageBuy$15.00
8/19/2024Noble FinancialBoost TargetOutperform ➝ Outperform$6.00 ➝ $10.00
8/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
7/23/2024EF Hutton Acquisition Co. IUpgradeStrong-Buy
7/16/2024Roth CapitalUpgradeStrong-Buy
7/16/2024Roth MkmInitiated CoverageBuy$20.00
7/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
6/18/2024HC WainwrightBoost TargetBuy ➝ Buy$8.00 ➝ $120.00
11/13/2023HC WainwrightReiterated RatingBuy ➝ Buy$120.00
10/9/2023HC WainwrightReiterated RatingBuy ➝ Buy$120.00
8/31/2023HC WainwrightReiterated RatingBuy ➝ Buy$120.00
3/24/2023HC WainwrightReiterated RatingBuy$120.00
3/3/2023Dawson JamesInitiated CoverageBuy$60.00
2/15/2023HC WainwrightReiterated RatingBuy$120.00
2/1/2023HC WainwrightReiterated RatingBuy$120.00
11/15/2022Maxim GroupLower Target$45.00
10/26/2022HC WainwrightInitiated CoverageBuy$120.00
5/23/2022Maxim GroupReiterated RatingBuy$90.00
11/12/2021Maxim GroupInitiated CoverageBuy$150.00
5/7/2021Maxim GroupReiterated RatingBuy$120.00
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.63 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 2 very positive mentions
  • 6 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/6/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 3 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

GeoVax Labs logo
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
Read More

Today's Range

Now: $0.38
Low: $0.38
High: $0.40

50 Day Range

MA: $0.51
Low: $0.37
High: $0.65

52 Week Range

Now: $0.38
Low: $0.37
High: $2.75

Volume

579,488 shs

Average Volume

497,309 shs

Market Capitalization

$11.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.64

Frequently Asked Questions

What sell-side analysts currently cover shares of GeoVax Labs?

The following equities research analysts have issued research reports on GeoVax Labs in the last year: Alliance Global Partners, D. Boral Capital, HC Wainwright, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for GOVX.

What is the current price target for GeoVax Labs?

0 Wall Street analysts have set twelve-month price targets for GeoVax Labs in the last year. Their average twelve-month price target is $7.50, suggesting a possible upside of 1,838.5%. Alliance Global Partners has the highest price target set, predicting GOVX will reach $8.50 in the next twelve months. D. Boral Capital has the lowest price target set, forecasting a price of $6.00 for GeoVax Labs in the next year.
View the latest price targets for GOVX.

What is the current consensus analyst rating for GeoVax Labs?

GeoVax Labs currently has 1 sell rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for GOVX.

What other companies compete with GeoVax Labs?

Other companies that are similar to GeoVax Labs include Werewolf Therapeutics, Telomir Pharmaceuticals, Medicus Pharma, Synaptogenix and ImmuCell. Learn More about companies similar to GeoVax Labs.

How do I contact GeoVax Labs' investor relations team?

GeoVax Labs' physical mailing address is 1900 LAKE PARK DRIVE SUITE 380, SMYRNA GA, 30080. The company's listed phone number is (678) 384-7220 and its investor relations email address is [email protected]. The official website for GeoVax Labs is www.geovax.com. Learn More about contacing GeoVax Labs investor relations.